The relationship between 25-hydroxyvitamin d and homocysteine in asymptomatic adults

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 2, 2014, Pages 633-638

  Amer, Muhammad ^a,b   Qayyum, Rehan ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOWARD UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; CARDIOVASCULAR DISEASES; FEMALE; HOMOCYSTEINE; HUMANS; MALE; MIDDLE AGED; NUTRITION SURVEYS; RISK FACTORS; VITAMIN D;

EID: 84893765929     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-3262     Document Type: Article

References (33)

1. Den Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. J Thromb Haemost. 2005;3(2):292-299.
2. Al-Obaidi MK, Philippou H, Stubbs PJ, et al. Relationships between homocysteine, factor VIIa, and thrombin generation in acute coronary syndromes. Circulation. 2000;101(4):372-371.
3. Kelly PJ, Rosand J, Kistler JP, et al. Homocysteine, MTHFR 677C->T polymorphism, and risk of ischemic stroke: results of a meta-analysis. Neurology. 2002;59(4):529-536.
4. McIlroy SP, Dynan KB, Lawson JT, Patterson CC, Passmore AP. Moderately elevated plasma homocysteine, methylenetetrahydrofolate reductase genotype, and risk for stroke, vascular dementia, and Alzheimer disease in Northern Ireland. Stroke. 2002;33(10): 2351-2356.
5. Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA. 1997;277(22):1775-1781.
6. Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991; 324(17):1149-1155.
7. Crider KS, Zhu JH, Hao L, et al. MTHFR 677C->T genotype is associated with folate and homocysteine concentrations in a large, population-based, double-blind trial of folic acid supplementation. Am J Clin Nutr. 2011;93(6):1365-1372.
8. Vaughn JD, Bailey LB, Shelnutt KP, et al. Methionine synthase reductase 66A->Gpolymorphism is associated with increased plasma homocysteine concentration when combined with the homozygous methylenetetrahydrofolate reductase 677C->T variant. J Nutr. 2004;134(11):2985-2990.
9. Jhee KH, Kruger WD. The role of cystathionine β-synthase in homocysteine metabolism. Antioxid Redox Signal. 2005;7(5-6):813-822.
10. Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA. 1993;270(22):2693-2688.
11. Ubbink JB, Vermaak WJ, van der Merwe A, Becker PJ. Vitamin B-12, vitamin B-6, and folate nutritional status in men with hyperhomocysteinemia. Am J Clin Nutr. 1993;57(1):47-53.
12. Vermeulen EG, Stehouwer CD, Twisk JW, et al. Effect of homocysteine- lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: a randomised, placebo-controlled trial. Lancet. 2000;355(9203):517-522.
13. Wang X, Qin X, Demirtas H, et al. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet. 2007; 369(9576):1876-1882.
14. Martí-Carvajal AJ, Solà I, Lathyris D, Karakitsiou DE, Simancas- Racines D. Homocysteine lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev. 2009;( 4): CD006612.
15. Miller ER 3rd, Juraschek S, Pastor-Barriuso R, Bazzano LA, Appel LJ, Guallar E. Meta-analysis of folic acid supplementation trials on risk of cardiovascular disease and risk interaction with baseline homocysteine levels. Am J Cardiol. 2010;106(4):517-527.
16. Lee M, Hong KS, Chang SC, Saver JL. Efficacy of homocysteinelowering therapy with folic acid in stroke prevention: a meta-analysis. Stroke. 2010;41(6):1205-1212.
17. Lips P. Vitamin D physiology. Prog Biophys Mol Biol. 2006;92(1): 4-8.
18. Bhalla AK, Amento EP, Clemens TL, Holick MF, Krane SM. Specific high-affinity receptors for 1,25-dihydroxyvitaminD3inhuman peripheral blood mononuclear cells: presence in monocytes and induction in T lymphocytes following activation. J Clin Endocrinol Metab. 1983;57(6):1308-1310.
19. Aihara K, Azuma H, Akaike M, et al. Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice. J Biol Chem. 2004;279(34):35798-36802.
20. Almerighi C, Sinistro A, Cavazza A, Ciaprini C, Rocchi G, Bergamini A. 1α,25-Dihydroxyvitamin D3 inhibits CD40L-induced pro-inflammatory and immunomodulatory activity in human monocytes. Cytokine. 2009;45(3):190-197.
21. Kriebitzsch C, Verlinden L, Eelen G, et al. 1,25-Dihydroxyvitamin D3influences cellular homocysteine levels in murine preosteoblastic MC3T3-E1 cells by direct regulation of cystathionine β-synthase. J Bone Miner Res. 2011;26(12):2991-3000.
22. Melamed ML, Michos ED, Post W, Astor B. 25-Hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med. 2008;168(15):1629-1637.
23. Amer M, Qayyum R. Relationship between 25-hydroxyvitamin D and all-cause and cardiovascular disease mortality.AmJMed. 2013; 126(6):509-514.
24. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 suppl 1):S1-S266.
25. Artaza JN, Mehrotra R, Norris KC. Vitamin D and the cardiovascular system. Clin J Am Soc Nephrol. 2009;4(9):1515-1522.
26. Andress DL. VitaminDin chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int. 2006;69(1): 33-43.
27. Koyama T, Shibakura M, Ohsawa M, Kamiyama R, Hirosawa S. Anticoagulant effects of 1α,25-dihydroxyvitaminD3onhumanmyelogenous leukemia cells and monocytes. Blood. 1998;92(1):160-171.
28. Zhang D, Fang P, Jiang X, et al. Severe hyperhomocysteinemia promotes bone marrow-derived and resident inflammatory monocyte differentiation and atherosclerosis in LDLr/CBS-deficient mice. Circ Res. 2012;111(1):37-49.
29. Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011;96(1):53-58.
30. Grant WB. Relation between prediagnostic serum 25-hydroxyvitamin D level and incidence of breast, colorectal, and other cancers. J Photochem Photobiol B. 2010;101(2):130-163.
31. Melamed ML, Muntner P, Michos ED, et al. Serum 25-hydroxyvitamin D levels and the prevalence of peripheral arterial disease: results from NHANES 2001 to 2004. Arterioscler Thromb Vasc Biol. 2008;28(6):1179-1185.
32. Amer M, Qayyum R. Relation between serum 25-hydroxyvitamin D and C-reactive protein in asymptomatic adults (from the continuous National Health and Nutrition Examination Survey 2001 to 2006). Am J Cardiol. 2012;109(2):226-230.
33. Looker AC, Pfeiffer CM, Lacher DA, Schleicher RL, Picciano MF, Yetley EA. Serum 25-hydroxyvitaminDstatus of the US population: 1988-1994 compared with 2000-2004. Am J Clin Nutr. 2008; 88(6):1519-1527.